Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of Adherence-enhancing Interventions on Adherence to Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia (TAKE-IT): A Quasi-experimental Pre-Post Intervention Multicenter Pilot Study.
Leader A, Benyamini N, Gafter-Gvili A, Dreyer J, Calvarysky B, Amitai A, Yarchovsky-Dolberg O, Sharf G, Tousset E, Caspi O, Ellis M, Levi I, De Geest S, Raanani P. Leader A, et al. Among authors: benyamini n. Clin Lymphoma Myeloma Leuk. 2018 Nov;18(11):e449-e461. doi: 10.1016/j.clml.2018.06.026. Epub 2018 Jun 25. Clin Lymphoma Myeloma Leuk. 2018. PMID: 30030034
Identifying Tyrosine Kinase Inhibitor Nonadherence in Chronic Myeloid Leukemia: Subanalysis of TAKE-IT Pilot Study.
Leader A, Gafter-Gvili A, Benyamini N, Dreyer J, Calvarysky B, Amitai A, Yarchovsky-Dolberg O, Sharf G, Tousset E, Caspi O, Ellis M, Levi I, Raanani P, De Geest S. Leader A, et al. Among authors: benyamini n. Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):e351-e362. doi: 10.1016/j.clml.2018.06.007. Epub 2018 Jun 12. Clin Lymphoma Myeloma Leuk. 2018. PMID: 30122203
Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.
Mahon FX, Boquimpani C, Kim DW, Benyamini N, Clementino NCD, Shuvaev V, Ailawadhi S, Lipton JH, Turkina AG, De Paz R, Moiraghi B, Nicolini FE, Dengler J, Sacha T, Takahashi N, Fellague-Chebra R, Acharya S, Wong S, Jin Y, Hughes TP. Mahon FX, et al. Among authors: benyamini n. Ann Intern Med. 2018 Apr 3;168(7):461-470. doi: 10.7326/M17-1094. Epub 2018 Feb 20. Ann Intern Med. 2018. PMID: 29459949 Clinical Trial.
Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life Study.
Luttwak E, Gatt ME, Lebel E, Lavi N, Tadmor T, Natalia K, Benyamini N, Horowitz N, Geva M, Suriu C, Avivi I, Trestman S, Mittelman M, Rouvio O, Cohen YC. Luttwak E, et al. Among authors: benyamini n. Clin Lymphoma Myeloma Leuk. 2020 Nov;20(11):e850-e857. doi: 10.1016/j.clml.2020.06.002. Epub 2020 Jun 11. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32624446
Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience.
Segman Y, Ribakovsky E, Avigdor A, Goldhecht Y, Vainstein V, Goldschmidt N, Harlev S, Horwitz N, Gutwein O, Gurion R, Itchaki G, Abadi U, Nemets A, Sofer O, Zektser M, Tadmor T, Dally N, Filanovsky K, Leiba M, Sarid N, Benyamini N, Herishanu Y, Ram R, Perry C, Avivi I. Segman Y, et al. Among authors: benyamini n. Leuk Lymphoma. 2021 Jan;62(1):118-124. doi: 10.1080/10428194.2020.1824069. Epub 2020 Sep 27. Leuk Lymphoma. 2021. PMID: 32981410
Characteristics and outcome of multiple myeloma patients presenting with anaemia only: A retrospective multi-centre study.
Shragai T, Gatt ME, Shaulov A, Katodritou E, Triantafyllou T, Lavi N, Pouli A, Sioni A, Vaxman I, Zektser M, Ganzel C, Benyamini N, Trestman S, Ziv-Baran T, Adam Y, Cohen YC, Avivi I. Shragai T, et al. Among authors: benyamini n. Leuk Res. 2021 Feb;101:106498. doi: 10.1016/j.leukres.2020.106498. Epub 2020 Dec 31. Leuk Res. 2021. PMID: 33453475 Clinical Trial.
47 results